movementdisorders.onlinelib...
Results
UDCA was safe and well tolerated, and only mild transient gastrointestinal adverse events were more frequent in the UDCA treatment group. Midbrain 31P-MRS demonstrated an increase in both Gibbs free energy and inorganic phosphate levels in the UDCA treatment group compared to placebo, reflecting improved ATP hydrolysis. Sensor-based gait analysis indicated a possible improvement of cadence (steps per minute) and other gait parameters in the UDCA group compared to placebo. In contrast, subjective assessment applying the MDS-UPDRS-III failed to detect a difference between treatment groups.
Conclusions
High-dose UDCA is safe and well tolerated in early PD. Larger trials are needed to further evaluate the disease-modifying effect of UDCA in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
First Red light therapy in Parkinsons study to be published by Australian researchers
Phase 2 Mesenchymal Stem Cell Trial in USA
Very interesting video on controversial issues regarding managing Parkinson’s at different stages (from 2 guys that seem smart).
Benfotiamine (Fat Soluble Form Of Vitamin B1) and AD
